Implementing the Jadelle implant for women living with HIV in a resource-limited setting: Concerns for drug interactions leading to unintended pregnancies

AIDS

Volumn 28, Issue 5, 2014, Pages 791-793

  Perry, Sarah H ^a,d   Swamy, Padma ^b   Preidis, Geoffrey A ^b   Mwanyumba, Anne ^c   Motsa, Nozipho ^d   Sarero, Hailu N ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Kingdom of Swaziland Ministry of Health Sexual and Reproductive Health Unit   (Swaziland)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LEVONORGESTREL; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE; CONTRACEPTIVE AGENT; LOPINAVIR; RITONAVIR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONDOM USE; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JADELLE IMPLANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWAZILAND; UNPLANNED PREGNANCY; ADOLESCENT; DRUG INTERACTION; HIV INFECTIONS; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; CONTRACEPTIVE AGENTS, FEMALE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MIDDLE AGED; NEVIRAPINE; PREGNANCY; PREGNANCY, UNPLANNED; RITONAVIR; SWAZILAND; YOUNG ADULT;

EID: 84897993557     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000177     Document Type: Article

References (7)

1. Swaziland MOH, ICAP, CHAI, SCHARP, Epicentre. Swaziland HIV Incidence Measurement Survey (SHIMS). First Findings Report. November 2012. p. 8.
2. Petruney T, Harlan SV, Lanham M, Robinson ET. Increasing support for contraception as HIV prevention: stakeholder mapping to identify influential individuals and their perceptions. PLoS One 2010; 5:e10781.
3. Jadelle Contraceptive Independence. Berlin, Germany. Bayer HealthCare: Social Healthcare Programs and Family Planning. Contraception. 2012; ISSN 0010-7824, 10.1016/.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013.
5. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz. Infect Dis Obstet Gynecol 2012; 2012:; 137192(s).
6. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr 2013; 62:534-539.
7. Lakhi N, Govind A. Implanon failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Healthcare 2010; 36:181-182.